2-(4-aminophenyl)benzothiazole and Colonic-Neoplasms

2-(4-aminophenyl)benzothiazole has been researched along with Colonic-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for 2-(4-aminophenyl)benzothiazole and Colonic-Neoplasms

ArticleYear
Synthesis, in vitro and in vivo cytotoxicity, and prediction of the intestinal absorption of substituted 2-ethoxycarbonyl-imidazo[2,1-b]benzothiazoles.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2001, Volume: 14, Issue:3

    The imidazobenzothiazole compounds 3-17 together with the imidazobenzoxazole 18, and the imidazobenzoimidazole 19 were prepared and their cytotoxic activity evaluated at the National Cancer Institute (NCI) for testing against a panel of approximately 60 tumor cell lines. Compounds 5, 7, 8, and 16 exhibited interesting in vitro cytotoxic activity. The most active imidazobenzothiazole derivative 8 was further evaluated as a cytotoxic agent in the hollow fiber assay and showed a score greater than the minimum values for xenograft testing together with a net cell kill. Comparison with the results displayed in the in vivo assay by standard antitumor drugs in clinical use revealed a significant in vivo activity of the benzothiazole compound. COMPARE analyses for compounds 4-19 against the NCI's standard agent database show poor or no correlation, and it might suggest for these compounds a mechanism of action unrelated to that of any known drug. Furthermore, the benzothiazole 8 did not show significant antitumor activity in a panel of two xenotransplanted tumors (i.e. colon and non-small cell lung tumors). By computing the polar surface area of compounds 3-19 with the MAREA computer program it was established that the most active compounds 5, 7, 8, and 16 should experience good intestinal permeability.

    Topics: Animals; Antineoplastic Agents; Benzothiazoles; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Drug Evaluation, Preclinical; Humans; Intestinal Absorption; Lung Neoplasms; Mice; Molecular Structure; Neoplasm Transplantation; Software; Structure-Activity Relationship; Thiazoles; Tumor Cells, Cultured

2001
2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity.
    British journal of cancer, 1998, Volume: 77, Issue:5

    2-(4-Aminophenyl)benzothiazole (CJM 126) elicits biphasic growth-inhibitory effects against a panel of oestrogen receptor-positive (ER+) and oestrogen receptor-negative (ER-) human mammary carcinoma cell lines in vitro, yielding IC50 values in the nM range. Substitutions adjacent to the amino group in the 2-phenyl ring with a halogen atom or methyl group enhance potency in sensitive breast lines (pM IC50 values). Transient biphasic dose responses were induced but rapidly eradicated after specific drug exposure periods. Two human prostate carcinoma cell lines were refractory to the growth-inhibitory properties of 2-(4-aminophenyl)benzothiazoles; IC50 values > 30 microM were obtained. Potency and selectivity were confirmed when compounds were examined in the National Cancer Institute's Developmental Therapeutics screen; the spectrum of activity included specific ovarian, renal, colon as well as breast carcinoma cell lines. Moreover, comparing 6-day and 48-h incubations, the exposure time-dependent nature of the biphasic response was corroborated. Differential perturbation of cell cycle distribution followed treatment of MCF-7 and MDA 468 cells with substituted 2-(4-aminophenyl)benzothiazoles. In MDA 468 populations only, accumulation of events in G2/M phase was observed. Two MCF-7 cell lines were established with acquired resistance to CJM 126 (IC50 values > 20 microM), which exhibit cross-resistance to substituted benzothiazoles, but equal sensitivity to tamoxifen and doxorubicin. Compared with standard anti-tumour agents evaluated in the National Cancer Institute in vitro cell panel, benzothiazoles revealed unique profiles of growth inhibition, suggesting a mode(s) of action shared with no known clinically active class of chemotherapeutic agents.

    Topics: Antineoplastic Agents; Benzothiazoles; Breast Neoplasms; Carcinoma; Cell Cycle; Colonic Neoplasms; DNA Replication; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estrogens; Female; Growth Inhibitors; Humans; Kidney Neoplasms; Male; Melanoma; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Skin Neoplasms; Structure-Activity Relationship; Thiazoles; Tumor Cells, Cultured

1998